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Abstract
Background: Chemotherapy dose delay and/or reduction lower relative total dose intensity (RTDI) and may affect
short- and long-term outcome of metastatic breast cancer (MBC) patients.
Methods: Based on 933 individual patients’ data of from 3 randomized MBC trials using an anthracycline and
taxane we examined the impact of RTDI on efficacy and determined the lowest optimal RTDI for MBC patients.
Results: Median time to disease progression (TTDP) and overall survival (OS) of all patients were 39 and 98 weeks.
Overall higher RTDI was correlated with a shorter TTDP (log-rank p = 0.0525 for 85% RTDI cut-off). Proportional
hazards assumption was violated, there was an early drop in the TTDP-curve for the high RTDI group. It was
explained by the fact that patients with primary disease progression (PDP) do have a high RTDI per definition.
Excluding those 114 patients with PDP the negative correlation between RTDI and TTDP vanished. However, non-
PDP patients with RTDI-cut-off levels <85% showed a shorter OS than patients with higher RTDI levels (p = 0.0086).
Conclusions: Optimizing RTDI above 85% appears to improve long-term outcome of MBC patients receiving first-
line chemotherapy. Lowering RTDI had no negative influence on short term outcome like OR and TTDP.
Background
Therapy of metastatic breast cancer (MBC) has improved
over the last decades probably due to sequential systemic
treatment in multiple lines [1]. Anthracyline and taxane-
based therapies are part of the standard of care in first line
MBC. More than 50% of patients receive sub-optimally
dosed adjuvant treatment. Evidence-based recommenda-
tions for chemotherapy dosing in the metastatic setting
are expected to be followed even less stringently, it is not
known whether this results in a detrimental course of the
disease and earlier death [2]. Over the past 40 years clini-
cal trials have sought to determine benefit of greater
chemotherapy dose intensity. The consequences of dose
delays and reductions are significant, potentially affecting
short and long-term outcomes as well as patient’sQ o L .
Maintaining the dose and schedule are of central concern
in delivery of chemotherapy. The Goldie-Coldman
hypothesis predicts that delivering higher doses of che-
motherapy agents reduces the survival probability of che-
motherapy-resistant clones [3,4]. The Norton-Simon
hypothesis advances previous theories by incorporating
the concept of chemotherapy schedule [5]. These hypoth-
eses highlight the role of dose and schedule and have sig-
nificantly influenced oncology practice. The intended dose
is usually reported as part of the design of clinical studies,
but a review of large randomized chemotherapy trials
conducted between 1990 and 2000 found that the relative
total dose intensity (RTDI) is poorly reported in the litera-
ture [6]. Bonadonna et al [7] as well as the surveys of
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proportion of patients with cancer are given less than 85%
of the suggested dose [8]. A retrospective analysis of com-
munity practice data from records of 20,799 patients with
early breast cancer (EBC) between 1997-2000 found that
the average actual RTDI was 79% [2]. In this analysis, 56%
of patients with EBC received less than 85% RTDI. Signifi-
cant dose reductions and treatment delays are common
clinical practice in the management of patients with pri-
mary breast cancer. Even more alarming picture might be
observed in patients with MBC, where dose delays and
reductions are common methods of reducing the toxicities
and maintain the QoL.
Therefore, in this analysis the impact of relative total
dose intensity in first line metastatic breast cancer
patients treated with anthracycline/taxane based therapy
has been investigated.
Methods
Study identification
We conducted a Medline literature search (Feb 2006) to
identify prospective randomized phase 3 clinical trials
which evaluated efficacy and safety of anthracycline/tax-
ane-based chemotherapy regimens in patients with MBC
and were published between 1995-2006. A supplemen-
tary search covered abstracts from the ASCO annual
meetings (1995-2006). The search produced 51 relevant
articles. Then, further limitations were added, i.e. com-
pleted MBC studies were eligible if: (i) they were phase
3 prospective interventional clinical trials performed in
accordance with GCP, (ii) they evaluated short (ORR)
and long-term (TTDP, OS) efficacy measures, clearly
specified dosing of chemotherapy, including guidance
for dose delays and reductions, collected toxicity data,
and had a minimum follow-up period of 24 months.
A total of 7 eligible studies were identified from the
original literature search. The key consideration for final
inclusion into the analysis was timely access to indivi-
dual patient data (by March 2006) to allow for a pro-
spective planning of this analysis. Accordingly, three
randomized clinical trials were included into this inte-
grated analysis.
1. CECOG: n = 258; phase 3 study of gemcitabine
(1000 mg/m
2 i.v. d1,4), epirubicin (90 mg/m
2 d1) and
paclitaxel (175 mg/m
2 d1), GET Q3W for a maximum of
8 cycles vs. FU (500 mg/m
2 d1), epirubicin (90 mg/m
2
d1), and cyclophosphamide (500 mg/m
2 d1), FEC Q3W
for a maximum of 8 cycles as first-line chemotherapy in
MBC [9].
2. AGO Mamma-1: n = 514; phase 3 study of epirubi-
cin (60 mg/m
2 d1) and paclitaxel (175 mg/m
2 d1), ET
Q3W compared with epirubicin (60 mg/m
2 d1) and
cyclophosphamide (600 mg/m
2 d1), EC Q3W for a
maximum of 10 cycles as a first-line chemotherapy in
MBC [10].
3. AGO Mamma-3: n = 164 of 340 randomized; phase
3 study of epirubicin (60 mg/m
2 d1) and paclitaxel (175
mg/m
2 d1), ET Q3W compared with paclitaxel (175
mg/m
2 d1) and capecitabine (2000 mg/m
2 days 1-14),
TX Q3W for a maximum of 6 cycles as a first-line che-
motherapy in MBC [11].
The TX arm of the Mamma-3 study was not included
into the pooled analysis, since the administration of
capecitabine p.o. Q2W did not match the inclusion
criteria.
All trials were performed according to the Declaration
of Helsinki.
Study population
This statistical analysis was based on individual subject
data of 934 patients obtained from the above specified
phase 3 MBC trials.
Objectives and outcome measures
The objectives of this study were to determine impact of
reduced Relative Total Dose Intensity (RTDI) on short-
term (Overall Response Rate, ORR) and long-term
(Time-to-Disease Progression, TTDP and Overall Survi-
val, OS) outcome measures, to identify potential predic-
tors for TTDP and OS and determine optimal RTDI for
MBC patients treated with the anthracycline and tax-
ane-based first-line treatment.
Indicators of chemotherapy delivery
Relative Total Dose Intensity (RTDI) is the ratio of
Actual Total Dose Intensity (ATDI) and Planned Total
Dose Intensity (PTDI), expressed as a percentage.
RTDI (%) =
ATDI
PTDI
× 100
Planned total dose intensity (PTDI) is the planned
dose intensity over the entire treatment duration, aver-
aged across the chemotherapy agents used. In case of
permanent treatment discontinuation, other than disease
progression (DP) or death, the remaining cycles are cal-
culated with the planned length and zero dose. For
patients who withdrew from chemotherapy due to DP
or death the PTDI was calculated based on the number
of cycles actually completed.
PTDI(mg/week) =
Planned Total Dose (mg)
planned duration of therapy (weeks)
Actual total dose intensity (ATDI) is defined as the
actual average dose intensity over the real treatment
duration
Loibl et al. BMC Cancer 2011, 11:131
http://www.biomedcentral.com/1471-2407/11/131
Page 2 of 8ATDI(mg/week) =
Actual Total Dose (mg)
duration of therapy (weeks)
Note that RTDI expresses the effect of reductions,
delays as well as premature discontinuations in a treat-
ment (due to the reasons other than disease progression
or death).
The maximal body surface area (BSA) for calculation
of dosage was restricted in the CECOG study at 2.2 m
2,
and in the Mamma-3 study at 2.0 m
2. The BSA was not
limited in the Mamma-1 study. RTDI was first calcu-
lated separately for each component of the chemother-
apy regimen (e.g. anthracycline). Then for each
combination chemotherapy regimen (e.g. EC) an average
across the components was taken to derive the RTDI of
the combination.
RTDIEC =
RTDIE + RTDIC
2
.
TTDP is defined as the time in weeks between the
date of first chemotherapy application and the date of
the first documented sign of disease progression or
death due to any cause. OS is defined as the time in
weeks between the date of first chemotherapy applica-
tion and death due to any cause. Patients who withdrew
consent or were lost to follow-up were censored at the
moment of the last contact.
Primary Disease Progression (PDP) is defined as the
disease progression or death which occurred before or
at the first primary disease status evaluation (i.e. within
first 2 (CECOG) or 3 (AGO-Mamma-1 and Mamma-3)
cycles).
Integrated analysis and statistical evaluation
We carried out an integrated analysis of the individual
patient data. Descriptive summaries of demographic and
disease characteristics for included patients were pre-
pared by study and for the integrated populations within
each treatment group.
Data were analyzed with SAS
® Version 9.2 for Win-
dows under SAS Enterprise Guide
® Version 4.1 (SAS
Institute Inc. Cary NC, USA).
Categorical parameters were summarized by the num-
ber and percentage of patients in each category. Contin-
uous parameters were summarized by mean, median,
minimum and maximum values. Two-sided 95% confi-
dence intervals were presented, where appropriate. All
statistical tests were two-sided. The default significance
level was 5%. For all multivariate regression models
(binary logistic, Cox) the models were selected with the
backward elimination with sls (significance level to stay)
= 0.2 starting with all potential predictors listed for the
model. RTDI was forced into the Cox and logistic
regression models because it is a key factor of interest.
Proportionality of hazards was assessed for the Cox
models with log-minus-log plots.
The following baseline covariates were assessed for
possible significant effects on the endpoints: age (years),
ECOG PS, ER/PgR status, histological tumor type (duc-
tal vs. lobular vs. other), nodal status at primary diagno-
sis (N0 vs N+), tumor size at primary diagnosis (T1-3
vs. T4), previous chemotherapy (none vs. non-anthracy-
cline vs. anthracycline containing), previous endocrine
therapy, metastatic site (low (bone, skin, lymphatic
nodes, lung only) vs. high risk (liver, CNS, lung+other))
and chemotherapy arm. The following planned predic-
tors were not considered as covariates since they were
not available for all three studies; HER/2/neu, tumor
grading and previous radiotherapy.
At first, univariate Cox-proportional hazards models
for TTDP and OS with continuous RTDI as a single
predictor were fit. A squared term for RTDI was tested
in order to account for potential non-linearity of rela-
tionship between RTDI and outcome. However, these
models fit poorly according to the supremum test for
the functional form [12]. The addition of the squared
term did not improve the situation, other possible trans-
formations of continuous predictor also seemed inap-
propriate. Therefore, all following Cox proportional
hazard’s models for TTDP and OS, both univariate and
multivariate anylsis, were finally fit for different binary
versions of RTDI for pre-specified cut-points (95%, 90%,
85%, 80% and 75%). The Kaplan-Meier estimators of
survival function were computed for each RTDI group,
the corresponding curves were presented graphically
and the log-rank test was performed to compare the
time-to-event outcome across RTDI groups [13].
Results
Baseline
934 patients were included in the final analysis accord-
ing to the inclusion criteria. 114 (12%) patients experi-
enced a Primary Disease Progression (PDP). One
patient had an implausible date of progression and was
excluded from all analyses. The median age of the study
population was 56 years. Baseline characteristics are
outlined in Table 1.
The median follow-up was 72 weeks for the whole
s t u d yp o p u l a t i o n( 6 7 . 0 wi nC E C O G ,7 5 . 0 wM a m m a - 1 ,
71.5w Mamma-3, respectively).
Overall 27.3% of the patients discontinued due to pro-
gression or death and 18.1% due to other, non specified
reasons. The rate of discontinuation was lowest (18.3%)
in the Mamma-3 trial (planned 6 cycles) and approxi-
mately 50% in the two other trials (planned up to 8 and
10 cycles). Dose reductions were mainly due to toxicity
(though it is unknown whether it was exactly according
to the protocol). The majority of dose delays (from 30%
Loibl et al. BMC Cancer 2011, 11:131
http://www.biomedcentral.com/1471-2407/11/131
Page 3 of 8to 50% for individual studies) were due to logistic rea-
sons or patients wish.
Primary outcome measure
T h em e d i a nR T D If o rt h ew h o l es t u d yp o p u l a t i o nw a s
95.5% (CECOG 88.8%, Mamma-1 95.6%, Mamma-3
99.6%), whereas the mean RTDI overall was 85.7%
(CECOG 81.2%, Mamma-1 85.6%, Mamma-3 93.0%).
Results of all 933 eligible patients showed that high
RTDI had a negative impact (p > 0.05 for all cuts except
90%) on TTDP in the univariate analysis. Patients with
higher RTDI had a shorter TTDP compared to those
with lower RTDI (85% RTDI level; 37 weeks vs. 43 weeks
(p = 0.0525); Figure 1). Proportionality of hazards was
violated. Adding a time-dependent term also did not
model the data adequately, since this non-proportionality
was caused by a short early drop in the Kaplan-Meier
curve for TTDP in the low RTDI group. However, the
analysis of TTDP excluding 114 (12%) patients with the
PDP who have high RTDI by definition showed no differ-
ence between high and low RTDI group (Figure 1 and 2).
The backward selection multivariate analysis for the dif-
ferent pre-specified RTDI cut-off levels excluding the
PDP revealed only the following factors as significant
prognostic factors: HR status, ECOG, metastatic site and
previous chemotherapy.
Secondary outcome measures
T h em e d i a nO Sf o rt h ew h o l es t u d yp o p u l a t i o nw a s9 8
weeks. The OS for all subjects, including patients with
PDP, showed a non significant trend in favor of patients
with high RTDI (Figure 3a). When patients with the PDP
(n = 114) were excluded from the analysis, the influence
of RTDI on OS became significant. The Kaplan-Meier
Table 1 Patient characteristics
Study Overall
N = 934
CECOG GET
vs FEC
N = 256
AGO
Mamma 1
N = 514
AGO
Mamma 3
N = 164
Age, years
median (range) 53.5 (29-74) 56.0 (28-75) 58.0 (21-76) 56.0 (21-76)
N%N%N%N%
HR status
ER and/or PgR positive 118 67.43 324 69.83 131 80.37 573 71.45
missing 81 50 1 132
Her2
positive - - - - 30 23.08 30 23.08
missing 256 514 34 804
Nodal status at first diagnosis
positive 164 65.08 282 65.58 95 67.86 541 65.82
missing 4 84 24 112
ECOG PS
0 122 47.66 237 46.11 104 65.00 463 49.78
1o r2 134 52.34 277 53.89 56 35.00 467 50.22
missing 0 044
Prior chemotherapy
none 126 49.22 325 63.98 96 58.54 547 58.94
non-anthracycline 130 50.78 162 31.89 34 20.73 326 35.13
anthracycline 0 0 21 4.13 34 20.73 55 5.93
missing 0 606
Prior endocrine therapy
yes 99 38.67 220 44.62 85 51.83 404 44.25
missing 02 1 0 2 1
Metastatic site
high-risk* 207 80.86 318 64.50 113 68.90 638 69.88
missing 02 1 0 2 1
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OS. (Figure 4a-e). The lower the cut-off level, the more
prominent was the effect of low RTDI on the OS
(RTDI<90% OS of 103 weeks, RTDI<85% OS of 96 weeks
and RTDI<75% OS of 93 weeks).
The hazard ratios calculated by Cox model are given in
Figure 3b. The multivariate analysis (n = 585) showed a
non-significant trend towards improved OS for patients
with high RTDI. Factors independently influencing
OS were HR status, ECOG, metastatic site, previous
chemotherapy, therapy arm (borderline significant).
The full set analysis showed partly negative correlation
between the RTDI and ORR for the 95% (p = 0.024) and
90% cut off. (Figure 5a) When patients with the PDP
were excluded, positive correlation was seen for all cuts
except 95%, which were significant for 85% cut and
lower. (Figure 5b).
Discussion
This pooled analysis based on individual patients’ data
from three randomized phase 3 clinical trials (recruited
1996-2005) was designed to address an important clini-
cal question, whether dose-delays and/or dose reduction
do impact long-term (TTDP, OS) and short-term (ORR)
outcome for patients with MBC treated with first line
anthracycline/taxanes-based therapy. To the best of our
knowledge, the prognostic value of RTDI on long and
short-term outcomes in MBC has not been systemati-
cally addressed, neither in a prospective nor retrospec-
tive fashion.
It is not possible to put our results into the context
with other MBC studies, because no comparable ana-
lyses were reported in this setting. The only published
data were generated in the adjuvant setting by Bona-
donna et al. [7]. They demonstrated that patients who
received 85% or more of the optimal dose of CMF had a
longer relapse free and OS. Patients with less than 85%
relative dose had a survival comparable to those without
adjuvant chemotherapy. These data are first of all based
on CMF as adjuvant treatment and second did not take
into account the administration period. That dose mat-
ters in the adjuvant setting has been shown by several
Figure 1 Kaplan-Meier curve for TTDP. A: Kaplan-Meier for TTDP;
85% RTDI level (all pts). The early drop in the curve for patients
with high RTDI is clearly shown. B: Kaplan Meier curve for TTDP;
85% RTDI level without patients with PDP.
Figure 2 Hazard Ratio for Time To Disease Progression (A) with
and (B) without patients with PDP.
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fied and high dose chemotherapy approaches [14,15].
However, population involved and the aims of treat-
ment in the advanced disease are different compared to
the adjuvant setting and several reasons other than the
physician’s decision may intervene in determining the
reduction/delay of chemotherapy treatment in patients
who by definition are not curable and may also have
some disease-related impairments which limit the admin-
istration of full dose therapy. Quality of life (QoL) is con-
sistently considered a main objective in evaluating the
impact of treatments in advanced disease. Treatment is
aimed to ameliorate disease-related symptoms but it may
also provoke toxicities impairing QoL. This has not been
considered in this analysis.
Looking at our entire study population, we did observe
that maintaining the planned first-line taxanes/anthracy-
clines-based therapy on time and schedule led to a
decreased TTDP and OR. We identified this as an arte-
fact driven by two main reasons: a significantly higher
number of PDPs (114 pts, 12%) than initially anticipated,
and our definition of RTDI for progressing patients. If a
patient progressed within 2 or 3 cycles of treatment, the
last dose/schedule was carried forward for remaining
planned cycles and used for calculation of the RTDI.
This led to an artificially high RTDI for 12% of the
patients with early progression. After adjustment for PDP
the median OS was significantly improved for patients
with high RTDI (e.g. for RTDI ≥85% 118 weeks com-
pared to 96 weeks in the group with RTDI <85%; p =
0.0086.
The TTDP was comparable for the patient popula-
t i o n sw i t hh i g ha sw e l la sl o wR T D I .T h e s eO Sr e s u l t s
were not confirmed to be significant in the multivariate
Cox model, probably due to the reduced patient num-
bers (n = 585) included in this analysis. The KM estima-
tion for the patients included in the multivariate analysis
showed an insignificant trend for improved OS with
higher RTDI. However, an influence by other factors
cannot completely be excluded. It is unusual that the
OS but not the TTDP was impacted by the RTDI. This
is in contrast to results of most recently published MBC
studies, where improvement of TTDP did not result in
improvement of the OS. It is well known that OS is
never influenced by the initial therapy alone, and that
subsequent multiple treatments, including second-line
chemotherapy, radiotherapy, supportive care, diet and
social environment play critical role. It might be that
patients who receive optimal RTDI in the 1
st line setting
will do so for the forthcoming therapy lines. This would
support the hypothesis that maintaining RTDI in the
first-line chemotherapy is also critical for OS of MBC.
Another objective of this study was to determine the
optimal RTDI cut-off level for studied population. We
found out that any reduction of RTDI level has negative
effect on OS. In our study, the significant improvement
of OS was observed starting from the RTDI of 85% (HR
1.32). This is probably due to the sample size in respec-
tive cut-off levels.
To determine which variables had independent prog-
nostic value and to control for the difference between
studies, we performed a multivariate analysis. In our ser-
ies of patients, ECOG 1,2 (vs. 0), high-risk metastasis
(vs. low-risk) and previous chemotherapy were asso-
ciated with significantly worse prognosis both for TTDP
and OS. Positive HR status was associated with
improved TTDP and OS. The strengths of our study
are: large sample size, the analysis is based on 934 indi-
vidual patient’s data; all three phase 3 trials investigated
the role of current standard treatment (taxane/anthracy-
cline-based chemotherapy); and the majority (73%) of
the data were generated in one country only, therefore
it is probable that second-line treatment algorithm and
supportive care management were similar for those 680
patients. The analysis also has some limitations. Its ret-
rospective nature which was addressed by prospective
planning of the analysis. One of the study (AGO-
Mamma-1) had a larger sample size as compared to two
other ones. Paclitaxel/capecitabine arm was excluded
from the analysis due to inaccurate dose/time reporting
Figure 3 Hazard Ratio for OS (A) with and (B) without patients
with PDP.
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available. Quality of life data were not evaluated in this
analysis. Lastly, most of the patients (680 pts) received
lower than currently recommended dose of epirubicin
(60 mg/m
2 in AGO-Mamma 1 and 3) which might have
impacted the outcome for those patients.
Conclusions
Optimizing RTDI above 85% for patients with MBC
appears therefore a reasonable goal seems to be impor-
tant to improve long-term outcome of MBC patients
receiving first-line anthracycline/taxane-based che-
motherapy. Lowering RTDI had no negative influence in
Figure 4 Kaplan-Meier for overall survival excluding patients with Primary Disease Progression (n = 820) according to RTDI binary
cuts. A: 95% (median OS: 112 weeks (95% CI [97-136]) for RTDI ≥ 95% vs. 104 weeks (95% CI [91-129]) for RTDI < 95%. B: 90% (The median OS
was 118 weeks (95% CI [103-138]) for RTDI ≥ 90% vs. 103 weeks (95% CI [86-120]) for RTDI < 90%.); C: 85% (The median OS was 118 weeks (95%
CI [103-136]) for RTDI ≥ 85% vs. 96 weeks (95% CI [83-119]) for RTDI < 85%). D: 80% (The median OS was 116 weeks (95% CI [103-133]) for RTDI
≥ 80% vs. 96 weeks (95% CI [77-124]) for RTDI < 80%.) E: 75% (The median OS was 113 weeks (95% CI [103-133]) for RTDI ≥ 75% vs. 93 weeks
(95% CI [76-119]) for RTDI < 75%.
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RTDI. Dose reductions and delays should only be
undertaken due to important reasons as unacceptable
toxicity impairing quality of life.
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